Management of primary biliary cirrhosis: From diagnosis to end-stage disease
Tóm tắt
Primary biliary cirrhosis (PBC) is one of the most common chronic cholestatic liver diseases affecting the adult population. The clinical presentation of PBC can be diverse, ranging from the presymptomatic individual to the patient with advanced liver disease. Initial evaluation to establish diagnosis and appropriate follow-up are very important in the life-long management of these patients. The primary medical treatment in PBC should focus on reducing the rate of disease progression. To this extent, treatment with ursodeoxycholic acid has been extensively evaluated and has been shown to improve liver biochemistries and survival in patients with PBC. Secondary medical management in PBC should address the treatment of complications of chronic cholestasis, hepatic cirrhosis, and liver failure. Liver transplantation remains the only established therapeutic approach in treatment of patients with end-stage PBC and the associated complications.
Tài liệu tham khảo
Kaplan MM: Primary biliary cirrhosis. N Engl J Med 1996, 335: 1570–1580.
Angulo P, Lindor KD: Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Disease 1999, 3:529–570.
Galperin C, Gershwin ME: Immunopathology of primary biliary cirrhosis. Baillieres Clin Gastroenterol 1996, 10:461–481. This comprehensive review summarizes the immunopathogenesis of primary biliary cirrhosis.
Dickson ER, Grambsch PM, Fleming TR, et al.: Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10:1–7.
Heathcote JE: Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999, 11:607–615.
Poupon RE, Balkau B, Eschwege E, et al.: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991, 324:1548–1554. A landmark study on the beneficial effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.
Angulo P, Batts Therneau TM, et al.: Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29: 644–647.
Lindor KD, Therneau TM, Jorgensen RA, et al.: Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996, 110:1515–1518. The authors present data on the effect of ursodeoxycholic acid treatment on survival in patients with PBC.
Jones EA, Bergasa NV: The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999, 11:623–631.
Wolfhagen FHJ, Sternieri E, Hop WCJ, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebocontrolled study. Gastroenterology 1997, 113:1264–1269.
Vleggaar FP, van Buuren HR, Wolfhagen FHJ, et al.: Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999, 11:617–621.
Olsson R, Mattsson L-A, Obrant K, et al.: Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999, 19:188–192.
Markus BH, Dickson ER, Grambsch PM, et al.: Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989, 320:1709–1713.
Kim WR, Wiesner RH, Therneau TM, et al.: Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998, 28:33–38.
Balan V, Batts KP, Porayko MK, et al.: Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993, 18:1392–1398.